论文部分内容阅读
目的比较硝苯地平、非洛地平、氨氯地平治疗高血压的成本一效果。方法选择90例高血压病人,随机分为3组:硝苯地平组(n=30),非洛地平组(n=30),氨氯地平组(n=30),对3组的成本一效果分析进行评价。结果3组治疗前收缩期血压(SBP)、舒张期血压(DBP)均显著下降(P<0.01),有统计学差异;3组治疗前后心率无统计学差异(P>0.05);但硝苯地平成本较非洛地平、氨氯地平低。结论从药物经济学角度分析,硝苯地平是治疗高血压最佳治疗方案。
Objective To compare the cost-effectiveness of nifedipine, felodipine and amlodipine in the treatment of hypertension. Methods Ninety hypertensive patients were randomly divided into three groups: nifedipine group (n = 30), felodipine group (n = 30), amlodipine group (n = 30) Effect analysis to evaluate. Results Before treatment, systolic blood pressure (SBP) and diastolic blood pressure (DBP) were significantly decreased (P <0.01), with statistical significance. There was no significant difference in heart rate between the three groups before and after treatment (P> 0.05) Land costs than felodipine, amlodipine low. Conclusion From the perspective of pharmacoeconomics, nifedipine is the best treatment for hypertension.